

NMNI editorial report, 2019

G. Grine¹, P.-E. Fournier² and M. Drancourt¹

1) Aix-Marseille University, IRD, MEPHI and 2) Aix-Marseille University, IRD, VITROME

Keywords: New microbes and new infections, report, New microbes, new infections, report 2019

Original Submission: 26 February 2020; **Accepted:** 26 February 2020

Article published online: 11 March 2020

Corresponding author: M. Drancourt, IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille, France.
E-mail: michel.drancourt@univ-amu.fr

Introduction

Since its launch in 2013, 7 years ago, New Microbes and New Infections (NMNI) has published a total of 602 out of 759 submitted papers retrievable in PubMed Central (Fig. 1). NMNI aims to provide access to an international forum for authors reporting facts in infectious and (primarily) tropical diseases, and in clinical microbiology, that are new in one particular place and country. Accordingly, NMNI acknowledges contributions from emerging research teams, offering authors the opportunity to publish in their own language in addition to English. In 2018, five papers were submitted in French, within the framework of Special Issues devoted to infections in Tunisia and Algeria (three and two papers, respectively), and were translated and published in both languages in 2019 after the corresponding author had approved the English translation. Likewise, in 2019, one manuscript was submitted in a non-English language (Russian). In the meantime, NMNI has been included in PubMed Central, obviously increasing its visibility and attracting the interest of authors and readers. At the end of 2019 the journal has been accepted for the Emerging Sources Citation Index.

Editorial structure

NMNI is an online-only journal, meaning that authors can submit their contributions at any time, and that accepted papers


are released in chronological order of acceptance. NMNI is reviewing papers in English, French, German, Spanish, Portuguese, Chinese, Russian, Arabic and Tamazight thanks to a panel of international Editors who are greatly thanked for their kind contributions to the editorial process. Accepted papers are translated into English and published both in the original language version and in English after the corresponding author has approved the English translation. Papers can be submitted in any of 12 categories with the understanding that papers must report reliable facts in infectious and tropical diseases and clinical microbiology that are new in one particular geographic region.

Submissions

In 2019, NMNI received 170 submissions. Of the 170 submitted papers, 95 (56%) have been accepted for publication and published (not including 46 papers currently under review or out for revision) versus 29 rejected papers (17%) (Fig. 1). In addition, these manuscripts came from a very much wider variety of countries, showing that the journal is sought as a publication venue by an increasing number of authors (Fig. 2). Fig. 3 represents the geographical origin of submitted papers in 2019, indicating that NMNI is on the way to achieving its main goal, which is the rapid promotion of discoveries in infectious and tropical diseases and clinical microbiology made by emerging research teams from all over the world.

After France, Iran is still the leading country for contributions, followed by India and Japan. The journal continues to make efforts to help the authors from countries with cultural and financial difficulties to improve the quality of their scientific output and to share their knowledge with the global scientific community.

A



B




FIG. 1. Submitted manuscripts and editorial outcomes 2015–2019 (Elsevier data).

Article types

A pre-filled form was launched in 2018 to further facilitate the writing and submission of contributions in the New Species Announcement section of NMNI. This form, dedicated to submission of new species announcements, has been designed and tested in our IHU Méditerranée Infection institute to make the submission process more convenient and homogeneous as well as faster to write. Training on how to complete this form is carried out during writing workshops, and the efficiency of the system has been proved even when students are

involved. Other scientific journals are welcome to copy and use this form for the announcement of new species.

In 2019 a new article type was added: Image in Clinical Microbiology.

NMNI reports

The current citation rate CiteScore is 1.71, the Source Normalized Impact per Paper (SNIP) is 0.630. Our next objective will be to submit an application to Thomson Reuters for indexing in the Web of Science.




FIG. 2. Number of submissions between 2016 and 2019 by article type.




FIG. 3. Geographical origin of submitted papers in 2019.




FIG. 4. Average editorial and publication speed for articles published in NMNI (Elsevier data).

Readership

Online readerships of NMNI continues to grow. The most cited paper has 305 citations [1], the second most cited has 62 citations [2].

Perspectives

The editorial speed from submission to first decision has increased slightly from 6.4 weeks in 2018 to 9.1 weeks in 2019 (Fig. 4). NMNI is striving to strengthen its Editorial Board even more in order to decrease the current processing time for online publication, which remains above its goal of a 2-month process for publication measured from initial submission. Also, NMNI will publish thematic issues devoted to current situations of infections in every country. The continuing efforts of the

Editorial Board will also enhance the chances of the inclusion in Thomson Reuters' impact factor listings.

Conflict of interest

The authors declare that there is no conflict of interest.

References

- [1] Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. *New Microbe New Infect* 2015;6:22–9.
- [2] Eckert C, Emirian A, Le Monnier A, Cathala L, De Montclos H, Goret J, et al. Prevalence and pathogenicity of binary toxin-positive *Clostridium difficile* strains that do not produce toxins A and B. *New Microbe New Infect* 2014;3:12–7.